ERK Kinase Inhibitors for Hyperproliferative Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperproliferative and neoplastic diseases, such as cancer, lack effective inhibitors for the ERK signaling pathway, which is frequently activated in various tumors, leading to uncontrolled cell growth and progression.
Innovation Solution
Development of specific compounds, represented by the formula I, which selectively inhibit ERK protein kinase activity by targeting key components of the ERK/MAPK pathway, thereby attenuating or eliminating ERK kinase activity in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for hyperproliferative and neoplastic diseases, then existing therapeutic options are available, but effective inhibition of the ERK signaling pathway is lacking
Solution Approach 1:
The patent segments the ERK signaling pathway into targetable components (ERK1, ERK2 kinases) and develops specific small-molecule inhibitors for each, allowing selective intervention at different points in the pathway rather than using broad-spectrum treatments
Solution Approach 2:
The patent changes the chemical parameters of the inhibitors by developing compounds with different structural features (formula I with various X1, X2, X3, X4 configurations) to optimize binding affinity and selectivity for ERK kinases, thereby improving treatment effectiveness
2Productivity
If ERK pathway is activated in tumors, then cell growth and progression are driven, but uncontrolled proliferation occurs
Solution Approach 1:
The patent applies preliminary anti-action by administering ERK inhibitors before tumors can progress further, blocking the phosphorylation cascade upstream of ERK activation to prevent the harmful proliferation from occurring in the first place
Solution Approach 2:
The patent introduces small-molecule compounds as intermediaries that bind to ERK kinases and prevent their activation, acting as a mediator between the activated RTK/Ras/BRAF pathway and the downstream cellular responses to block the harmful signal transmission
Data Source
AI summary
Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.